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TAG           -Tri acyl glycerol 
TNF α        -Tumor necrosis factor alpha 
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MAP           - Mitogen activated protein kinase 
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RNS            - Reactive nitrogen species 
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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Diabetes mellitus is a heterogeneous group of metabolic disorders characterized by 
chronic hyperglycemia resulting from defects in insulin secretion, insulin action or both 1.  
It is classified into 2 major types: insulin dependent (Type 1) and non-insulin dependent 
(Type 2) 2. 
Type 1 diabetes mellitus is characterized by a specific destruction of the pancreatic beta 
cells mostly associated with immune mediated damage 3. 
Type 2 diabetes mellitus is characterized by a gradual change in glucose homeostasis due 
to insulin resistance and/or reduced insulin secretion 4. 
Type 2 diabetes mellitus is now taking its place as one of the main threats to human 
health in the 21st century5.  The World Health Organization (WHO) has estimated that by 
2025 there will be about 300 million people living with diabetes worldwide, with India 
alone contributing a massive 57.2 million 6. 
Though the metabolic derangements in Type 1 diabetes can be easily explained due to 
lack of insulin, for Type 2 diabetes it is multi-factorial influenced by genetic and 
environmental factors.  
  
 
 
Oxidative stress plays an important role in the pathogenesis of Type 2 diabetes and its 
complications 7. In diabetic patients there is a significant decrease in the  
activity of enzymatic antioxidant defense system like Superoxide dismutase, glutathione 
reductase, glutathione peroxidase and catalase. 8 
Reactive oxygen species (ROS) generated from chronic hyperglycemia in these patients 
disrupts the critical balance between oxidants and antioxidants 9 and is implicated in the 
development of long-term microvascular and macrovascular complications associated 
with high morbidity and mortality in these patients 10. 
Free radicals are highly reactive molecular species with an unpaired electron that can 
cause damage to nucleic acids, proteins and lipids in the cell membrane and plasma 
lipoproteins. Tissue damage caused by these free radicals is often termed as “Oxidative 
damage”11. 
Red blood cells (RBCs) are highly susceptible to oxidative damage as they are the first 
cells to be exposed to oxidative stress. Presence of high cellular concentration of oxygen 
and hemoglobin, lack of nucleus and mitochondria, inability to synthesize enzymes and 
protein make RBCs vulnerable to oxidative stress 12. 
Therefore, structural damage like crenated edges and Heinz bodies in RBCs caused by 
ROS can be used as a marker of oxidative stress in Diabetes mellitus. 
 
 
 
 
The level of antioxidants is reduced in diabetic patients and supplementation of non 
enzymatic antioxidants like Vitamin E and C can reduce this oxidative damage. 
Therefore in this study RBC morphology is used as a marker of oxidative stress in Type 2 
Diabetes and the effect of antioxidants like Vitamin E and C is studied in reversing this 
oxidative damage. 
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                                    LITERATURE REVIEW        
                                    DIABETES MELLITUS 
DEFINIITON 
Diabetes mellitus is characterized by chronic hyperglycemia with disturbances of 
carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, 
insulin action, or both. 13 
 
ETIOLOGICAL CLASSIFICATION 1 
1. Type 1 (beta cell destruction leading to absolute insulin deficiency) 
 Autoimmune  
 Idiopathic 
 
2. Type 2 (hyperglycemia, insulin resistance and relative insulin deficiency) 
 
3. Other specific types:  - Genetic defects of β-cell function/insulin action 
                             - Endocrinopathies 
                             - Drug- or- chemical-induced 
                             - Infections 
 
4. Gestational diabetes. 
 
 
 
EPIDEMIOLOGY 6,7 
The worldwide prevalence of Diabetes Mellitus has risen dramatically over the past two 
decades. The WHO has estimated a rise from an about 150 million cases in 2000 to 300 
million by 2025. Although the prevalence of both type 1 and type 2 DM is increasing 
worldwide, the prevalence of type 2 DM is rising much more rapidly due to increasing 
obesity and reduced physical activity. This is true in most countries, and 6 of the top 10 
countries with the highest rates are in Asia with India topping the list. 
 Diabetes mellitus increases with aging. The prevalence is similar in men and women 
throughout most age ranges (10.5% and 8.8% in individuals >20 years) but is slightly 
greater in men >60 years. Worldwide estimates project that in 2030 the greatest number 
of individuals with diabetes will be in the range of 45–64 years. 
 
TYPE 1 DIABETES MELLITUS: 1,6 
Type 1 diabetes occurs primarily due to β–cell destruction which produces a state in 
which insulin is required for survival.  
It is sub-classified as: 
 
  Type 1A: immune-mediated 
  Type 1B: idiopathic 
 
 
 
TYPE 2 DIABETES MELLITUS: 
Type 2 diabetes is the commonest form of diabetes worldwide.  These patients usually 
have insulin resistance with a state of relative, rather than absolute, insulin deficiency. 
The specific etiology of this form of diabetes is not known. Although these patients do 
not need insulin therapy to survive, ultimately many require it for control of blood 
glucose. Type 2 diabetes is associated with progressive β -cell failure with increasing 
duration of the disease.1 
 
PATHOGENESIS6,7 
Type 2 diabetes appears to develop due to a complex interplay of acquired (diet- or 
obesity- or stress related) and genetically programmed insulin resistance wherein the β-
cells of the pancreas fail to produce the extra insulin needed to maintain normal blood 
glucose levels. 
The relationship between plasma insulin and glucose in these patients can be depicted as 
occurring in 3 phases:  
 Phase I:  glucose levels are normal because of an underlying hyperinsulinemia which 
occurs to compensate for the insulin resistance at the level of the muscle, liver and 
other tissues.  
 
 
 Phase II: insulin resistance and compensatory hyperinsulinemia progress but the 
pancreatic β-cells are no longer able to sustain the hyperinsulinemic state. Impaired 
glucose tolerance, characterized by elevations in postprandial glucose, then develops.  
 Phase III: A further decline in insulin secretion and an increase in hepatic glucose 
production lead to overt diabetes with fasting hyperglycemia. Ultimately, β-cell 
failure occurs. 
 
RISK FACTORS: 
 
1. OBESITY:   
In obesity there is an increase in pro-inflammatory molecules called “adipokines” that 
induce systemic insulin resistance by direct effects on insulin signaling, down-regulation 
of genes needed for normal insulin action and negative regulation of PPARα.14 Increase 
in visceral fat mass leads to unrestrained lipolysis. This elevates circulating FFA levels 
resulting in an increase in the delivery of FFA to the liver by the portal vein. This leads to 
hepatic insulin resistance and decreased insulin clearance, with secondary effects of 
peripheral insulin resistance.15 
 
2. PHYSICAL ACTIVITY:  
Physical activity has been found to be inversely related to future risk of diabetes in most 
populations. Increased physical activity reduces the risk of obesity. This is related to 
 
 
acute and long-term improvements in insulin sensitivity and reduction in insulin 
concentrations.16 
 
 
3. ENVIRONMENTAL INFLUENCES:17,18  
Sedentary life style, Dietary habits (consumption of high fat, low fibre diet) have been 
shown to increase the risk of diabetes in most populations. 
 
4.GENETIC FACTORS:1 
A strong genetic basis is suggested by the high prevalence of insulin resistance in certain 
populations. These include the Nauru Islanders of the Pacific, the Pima Indians in 
Arizona, and the urban Wanigela people in Papua New Guinea. Also, there is a nearly 
100% concordance in diagnosis of type 2 diabetes between monozygotic twins but only a 
20% concordance between dizygotic twins. 
 
5.STRESS AND HORMONAL IMBALANCES1 
During exercise and under conditions of stress, catecholamines are released from the 
adrenal medulla or by sympathetic nerve terminals in the pancreas. They activate α2-
adrenoceptors in β-cells of pancreas and reduce insulin secretion and increase glucagon 
release. Increase in counter-regulatory hormones (glucagon, epinephrine etc) creates a 
 
 
hormonal imbalance resulting in elevated blood glucose. This partly accounts for the 
worsening glycemic control seen in individuals with diabetes who are under severe stress.  
 
CLINICAL PRESENTATION 19,20 
 
The clinical onset may be over several months to years, particularly in older patients. 
Polyuria (increased frequency of micturation), Polydipsia (increased thirst), Polyphagia 
(increased appetite) and weight loss are the most common symptoms. These may be 
accompanied by other complaints such as lack of energy, visual blurring (owing to 
glucose-induced changes in refraction), or pruritis vulvae or balanitis due to Candida 
infection. 
Patients with Type 2 diabetes may be asymptomatic and diagnosed only incidentally on 
routine examination. 
 
PHYSICAL EXAMINATION 19,20 
A complete physical examination in diabetics should include : 
- Weight or BMI,  
- Blood pressure 
- Retinal examination,  
- Peripheral pulses.  
 
 
- Lower extremities for peripheral neuropathy, calluses, superficial fungal infections, nail 
changes, ankle reflexes, and foot deformities (such as hammer or claw toes and Charcot  
foot)  to identify sites of potential skin ulceration. 
- Teeth and gums for periodontal disease  
- Acanthosis nigricans for insulin resistance.  
 
COMPLICATIONS 19 
ACUTE COMPLICATIONS 
 Diabetic ketoacidosis 
 Non ketotic hyperglycemic hyperosmolar coma 
CHRONIC COMPLICATIONS 
 Micro vascular 
      - Retinopathy                  - Neuropathy                - Nephropathy  
 Macro vascular 
   -  Coronary artery disease                                 - Cerebrovascular disease 
   -  Peripheral arterial disease 
 Others  
  - Gastro intestinal (gastroparesis/diarrhoea) 
  - Genitor urinary (uropathy /sexual dysfunction) 
  - Dermatological infections 
  - Cataract/Glaucoma 
 
 
  - Periodontal disease 
INVESTIGATIONS 19,20: 
 Blood sugar level: Fasting and Post Prandial.  
 Urine sugar level (not reliable) 
TO ASSESS THE DEGREE OF GLYCEMIC CONTROL 
 HbA1C  
FOR DIABETES RELATED CONDITIONS: 
 Full blood count 
 Urine for protein 
 Serum Urea and Creatinine (renal function tests) 
 Serum electrolytes 
 Serum lipid profile 
 Liver biochemistry 
 Fundus examination 
 ECG 
DIAGNOSTIC CRITERIA21 
 Symptoms of diabetes plus random blood glucose concentration >200 mg/dL 
(11.1mmol/L) or  
 
 
 Fasting plasma glucose >126 mg/dL (7.0 mmol/L) or  
 Two-hour plasma glucose  >200 mg/dL (11.1mmol/L)  during an oral glucose 
tolerance test or 
 HbA1c > 6.5% 
 
MANAGEMENT 22,23 
1. Glycemic control 
 Specific medications 
2. Treatment of associated conditions 
 Dyslipidemia 
 Hypertension  
 Obesity etc. 
3. Screening and management of complications 
 Retinopathy 
 Nephropathy 
 Neuropathy 
 Cardiovascular diseases 
 
 
 
 
GOALS OF THERAPY IN DIABETES 21 
INDEX VALUE 
HbA1c  <7.0% 
Pre prandial capillary plasma glucose 70-130 mg/dl 
Post prandial capillary plasma glucose  <180 mg/dl 
Blood pressure <130/80 mmHg 
 
 
NON PHARMACOLOGICAL MANAGEMENT1: 
1. Diet management 
 Adequate amount of carbohydrates (40%), rich in dietary fibre, low in 
saturated fat. 
2. Exercise 
 Aerobic activity 5-7 days/week, at a level that can be sustained for at least 
30 minutes, with the maximum heart rate not any higher than 60% to 70% 
above the resting. 
3. Stress reduction 
 Yoga, meditation ,relaxation therapy 
 Breathing exercises. 
 
 
 
MEDICAL MANAGEMENT21,22,23 
ORAL HYPOGLYCEMIC AGENTS (OHA) 
A. Drugs acting by release of insulin 
1. Sulfonylureas 
 First generation :       Chlorpropamide, Tolbutamide  
 Second generation:    Glibenclamide, Glipizide, Gliclazide,  Glimepride 
2. Meglitinide analogues:  Repaglinide, Nateglinide 
3. Glucagon like peptide (GLP 1 ) receptor agonists  (injectables) : Exenatide, 
Liraglutide 
4. Dipeptidyl peptidase -4 (DPP 4) inhibitors: Sitagliptin, Vildagliptin, 
Saxagliptin, Alogliptin, Linagliptin 
 
B. Reducing insulin resistance 
1. Biguanides:                Metformin 
2. Thiazolidinediones:   Pioglitazone 
C. Miscellaneous 
1. α glucosidase inhibitors:      acarbose, miglitol, voglibose 
2. Amylin analogues :               Pramlintide  
3. Dopamine (D2) receptor agonists:       Bromocriptine  
4. Sodium – Glucose cotransport -2 (SGLT -2) inhibitor:   Dapaglifozin  
 
 
 
SULFONYLUREAS: 
Blocks ATP sensitive potassium channels in pancreatic β-cells 
Adverse Effects:  Hypoglycemia, weight gain. 
MEGLITINIDES/D-PHENYLALANINE ANALOGUES: 
 K ATP channel blockers 
Adverse Effects: Dizziness, dyspepsia, flu like symptoms 
GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS  
GLP-1 is an important incretin released from the gut in response to ingested glucose 
 Induces insulin release from β-cells 
 Inhibits glucagon release from α-cells 
 Slows gastric emptying and suppresses appetite  
Adverse Effects: Nausea, vomiting, diarrhoea  
 
DIPEPTIDYL PEPTIDASE-4 (DPP) INHIBITORS: 
DPP -4 causes rapid degradation of endogenous GLP-1 which is an insulin secretagogue. 
 Competitive and reversible inhibitor of DPP 4 
 
 
 Decreases metabolism of GLP-1, potentiates its action 
Adverse Effects: Nausea, loose stools, allergic reactions 
BIGUANIDES (METFORMIN) 
AMPK  (AMP dependent protein kinase) activator 
 Inhibits  hepatic glucose production and release 
 Enhances insulin mediated glucose uptake in peripheral tissues 
 Promotes peripheral glucose utilization 
Uses: 
 First line drug for all Type 2 diabetics 
 Good anti hyperglycemic action 
 Promotes weight loss 
 Potential to prevent diabetic complications 
Adverse Effects: GI intolerance, metallic taste, megaloblastic anemia 
THIAZOLIDINEDIONES: 
 Agonist of PPAR ϒ (peroxisome proliferator activated receptor) 
 Enhances transcription of insulin sensitive genes and increases glucose uptake in 
fat and muscle. 
Adverse Effects: Weight gain, precipitation of Congestive heart failure, hepatotoxicity 
 
 
 
α-GLUCOSIDASE  INHIBITORS: 
 Prevents  the conversion of complex carbohydrates to simple carbohydrate by α- 
glucosidase inhibition and reduces its absorption 
Adverse Effects: GI disturbances, elevation of liver enzymes 
AMYLIN ANALOGUES: 
 Delays gastric emptying 
 Suppresses glucagon secretion 
Adverse Effects: Nausea, hypoglycaemia 
BROMOCRIPTINE (D2 AGONIST): 
 Dopaminergic control over circadian rhythm of anti-insulinic hormones to reduce 
insulin resistance 
 Used as an adjuvant to other first line drugs 
SGLT-2 INHIBITORS: 
 SGLT-2 causes re-absorption of glucose in proximal tubules of kidney 
 Inhibition of SGLT 2 causes glucosuria and lowers blood glucose level 
Adverse Effects: Urinary infections, electrolyte imbalances. 
 
 
 
INSULIN 
Decreases blood glucose by 
 Increasing entry of glucose in muscle and fat 
 Inhibiting glycogenolysis 
 Increasing glycolysis 
PREPARATIONS: 
 Conventional preparations 
 Obtained from pork and beef 
 Less costly 
 Produces allergic reactions 
 Human insulin  
 Prepared from recombinant DNA technology 
 Allergic reactions are rare 
 Costlier 
 Nasal insulin 
 Powdered form of recombinant human insulin 
 Delivered through an inhaler in to lungs 
 Helps in avoiding daily injections but costly. 
 
 
 
 
TYPES OF INSULINS 
 Ultra short acting 
 Lispro                   - Glulisine                   - Aspart 
 Short acting 
 Regular                                                    - Semi lente insulin 
 Intermediate acting 
 Lente                                                       - Neutral protamine hagedron 
 Long acting 
 Ultra lente                                              - Protamine zinc 
 
INDICATIONS OF INSULIN THERAPY 
 All cases of Type 1 diabetes 
 Type 2 diabetes 
 Not controlled on oral hypoglycaemic drugs 
 In pregnancy 
 Complications like DKA and Hyperosmolar hyperglycaemic state 
 To tide over stressful conditions like infection and surgery. 
 
 
 
 
                                                   INSULIN24 
 Insulin is a peptide hormone secreted by beta cells of the pancreas. 
 Insulin is first synthesized as a single polypeptide chain called preproinsulin (110 
amino acid), which is the processed to proinsulin and finally cleaved to form insulin 
and C-peptide. 
 Insulin (51 amino acids) has two, A(21 a.a) and B (30 a.a) chains linked by disulphide 
linkages.  
 Equimolar concentrations of insulin and C-peptide are secreted with insulin having a 
half life of 5-6 minutes and C-peptide a half life of 30 minutes. 
 
 
 
 
 
 
STIMULUS FOR SECRETION 25 
 Insulin secretion is an effectively regulated process designed to provide a stable 
concentration of glucose in blood during both fasting and fed state. 
 Factors which increase the release of insulin are: 
           - Carbohydrate rich food : increases blood glucose levels which is the most 
important stimulus for insulin secretion. Glucokinase in liver and pancreatic β cells 
converts blood glucose to glucose 6- phosphate. In β cells of pancreas it functions to 
detect high concentrations of glucose, converting it to glucose 6 phosphate which 
stimulates insulin secretion. 
           - Amino acids 
           - Fatty acids 
           - Ketone bodies 
           - GI hormones : also called incretins eg: Glucagon like peptide-1 (GLP-
1),Gastric- inhibiting polypeptide (GIP), cholecystokinin 
 
INHIBITORS OF SECRETION 25 
 Decreased blood glucose or hypoglycemia 
 
 
 Stress, severe exercise, trauma : due to activation of the sympathetic  nervous system 
and release of epinephrine. 
  Hormones : Somatostatin reduces the insulin secretion 
 Excessive gluconeogenesis. 
 
BIPHASIC RESPONSE  
 Insulin secretion to glucose is a biphasic response. 
 In the normal post-absorptive period, low basal levels of circulating insulin are 
maintained through constant β-cell stimulation. This suppresses lipolysis, proteolysis, 
and glycogenolysis. 
 A burst of insulin secretion occurs within few minutes of ingesting a meal, in 
response to transient increases in the levels of circulating glucose and amino acids. 
This lasts for up to 15 minutes and is followed by the postprandial secretion of 
insulin.22 
 
 
 
 
 
 
MECHANISM OF ACTION:26 
 Insulin action is mediated through insulin receptors which belong to the tyrosine 
kinase family.  
 Insulin receptor has 2 extracellular α and 2 transmembrane  β subunits. 
 The α subunit binds with insulin while the β subunit gets phosphorylated and mediates 
tyrosine kinase activity. 
 Activation of this receptor initiates phosphorylation of other intracellular proteins like 
Insulin Receptor Substrates (IRS)  which  interact with effectors and amplify the 
signaling process. 
 This plays an important role in Glucose disposal after meal ingestion. 
ACTIONS OF INSULIN27 
a) CARBOHYDRATE METABOLISM: 
 Adipose tissue  
-↑ Glucose uptake (via upregulation of GLUT-4 receptors) 
 Muscle 
 -↑ Glucose uptake (via upregulation of GLUT-4 receptors) 
 -↑Glycogen synthesis (activated Glycogen synthase enzyme) 
 Liver 
 
 
-↓Glucose output due to ↓ gluconeogenesis, increased glycogen synthesis and 
increased glycolysis. 
    b) PROTEIN METABOLISM: 
 Muscle 
-↑Amino acid uptake and protein synthesis in ribosomes 
-↓protein catabolism 
-↓release of gluconeogenic amino acids 
 
 Liver 
-↑protein synthesis 
c)  LIPID METABOLISM: 
 Adipose tissue  
 ↑fatty acid synthesis 
-↑triglyceride deposition 
-inhibition of hormone sensitive lipase 
 Muscle 
-↑ketone uptake 
 Liver 
-↓ketogenesis 
-↑lipid synthesis. 
 
 
 
                                   ANTI INSULIN HORMONES 28 
1. Pancreas  
 Glucagon 
 Somatostatin (from delta cells) – inhibit both insulin and glucagon but more 
prominent effect on insulin- hyperglycemia 
 
2. Adrenal medulla  
 Epinephrine 
                                        
3. Adrenal cortex  
 Glucocorticoids:  stimulates gluconeogenesis and  ↓ utilization of glucose 
by extra hepatic tissues 
     4. Anterior pituitary gland 
 Growth hormone:  Promotes gluconeogenesis and glycogenolysis in liver 
and decreases glucose utilization by muscles 
                                    
 ACTH    - Stimulates production of steroids in adrenal cortex and enhanced 
release of cortisol. 
 
 
 
 
 
 
                                                  GLUCAGON28 
 
 Glucagon is a polypeptide hormone secreted by the alpha cells of the pancreas. 
 
 It is composed of 29 amino acids that are arranged in a single polypeptide chain. 
 
 Glucagon is synthesized as a large precursor molecule (preproglucagon) which is 
converted to glucagon through a series of proteolytic cleavages similar to insulin 
biosynthesis. 
 
Physiology of glucagon 27,29 
 
Glucagon is secreted by the alpha cells of pancreas directly into the portal vein and 
carried to the liver. It has a circulating half life of 5-10 mins and is degraded primarily by 
the liver. 
 
The most important physiologic action of glucagon occurs during the postabsorptive and 
fasting states. Glucagon stimulates glycogenolysis, gluconeogenesis, and ketogenesis by 
the liver, and lipolysis in adipose tissue. 
 
 
 
 
In states of low blood glucose, the central nervous system triggers neural–sympatho-
adrenal hormones to counteract this hypoglycemia. The ventromedial hypothalamus is 
an important sensor of hypoglycemia and  initiates certain neural afferent signals which 
stimulate counter-regulatory responses by way of  secretion of catecholamines, glucagon, 
growth hormone, and glucocorticoids. 
 
 
Stimulus for glucagon secretion25 
 
1. Low blood glucose: A reduction in the plasma glucose level is the main stimulus for 
glucagon release. During prolonged or overnight fasting, elevated levels of glucagon 
prevent the development of hypoglycemia. 
 
2. Amino acids: Amino acids from meals rich in proteins stimulate the release of both 
glucagon and insulin. The glucagon prevents the hypoglycemia which would otherwise 
occur due to increased insulin release following a protein rich meal. 
 
3.Epinephrine: Stimulation of the sympathetic nervous system causes increased levels of 
circulating epinephrine (by adrenal medulla), and/or norepinephrine both of which 
enhance glucagon release. During periods of stress or severe exercise, the elevated  
 
 
 
 
epinephrine levels can increase glucagon secretion regardless of the blood glucose 
concentration. 
 
 
 Inhibitors of glucagon secretion25 
 
1. Carbohydrate rich meal results in elevation of blood glucose level. This inhibits the 
release of glucagon 
2. Insulin is released when blood glucose level rises. Insulin inhibits the release of 
glucagon.  
3. Somatostatin: is a hormone produced from delta cells of pancreas. It inhibits release 
of both insulin and glucagon but its action on insulin is more marked. 
4. Glucagon like peptide 1(GLP-1): is an incretin released from the gut in response to 
oral glucose. It inhibits glucagon release by acting on GLP-1 receptors on the alpha 
cells of pancreas. 
 
 
Effects of glucagon25,29 
 
1.Effects on carbohydrate metabolism: Glucagon causes an enhanced breakdown of 
liver (not muscle) glycogen, resulting in an immediate rise in blood glucose levels. 
 
 
 
Glucagon also inhibits the enzyme pyruvate kinase of the glycolytic pathway due to 
which PEP (phospho enol pyruvate) is unable to continue in glycolysis and enters the 
gluconeogenesis pathway instead.  This causes inhibition of  hepatic glycolysis and 
stimulatation of  gluconeogenesis by glucagon. 
 
2.Effects on lipid metabolism: Glucagon activates lipolysis in adipose tissues releasing 
free fatty acids into circulation. These are taken up by liver and oxidized to acetyl 
coenzyme A, excess of which is diverted to ketone bodies synthesis. 
 
3.Effects on protein metabolism: Glucagon increases the hepatic uptake of amino acids, 
which are subsequently used as substrates for gluconeogenesis.  
 
4.Effect on Red blood cells . The mature erythrocyte lacks mitochondria and is 
completely dependent on glycolysis for ATP production.  This ATP is required to meet 
the metabolic needs of the RBC and for maintaining the flexible biconcave shape of the 
RBC, which allows it to squeeze through narrow capillaries.25  
The final step in glycolysis is the synthesis of pyruvate from phosphoenolpyruvate 
catalyzed by the enzyme pyruvate kinase. 
 
This enzyme is hormonally activated by insulin and inhibited by glucagon via the 
 
 
c-AMP pathway. Inhibition of  pyruvate kinase by  glucagon leads to a deficiency of 
ATP.  ATP is necessary for the maintenance of the normal biconcave disc shape of the 
RBC which allows it to squeeze through narrow capillaries.  Alterations in the shape lead 
to poor red cell deformability and early phagocytosis by cells of the reticulo-endothelial 
system, particularly the spleen. 25 
This premature lysis of red blood cells results in hemolytic anemia. 
 
ROLE OF GLUCAGON IN INSULIN RESISTANCE 
 
Glucagon opposes the actions of insulin (physiological antagonist) in the following 
ways contributing to insulin resistance:25 
 
A) PROMOTES GLUCONEOGENESIS by 3 mechanisms.  
 
Gluconeogenesis is the process of synthesizing glucose or glycogen from non 
carbohydrate precursors like glucogenic amino acids, lactate, glycerol and propionate. 
 
The major tissues for gluconeogenesis are liver and kidney with kidney contributing 
upto 40% of gluconeogenesis in starvation.  
 
 
 
Excess gluconeogenesis occurs in critically ill patients in response to injury, infection and 
stress causing hyperglycemia which causes changes in osmolarity of body fluids, reduced 
blood flow, intracellular acidosis and production of superoxide radicals. Excessive 
gluconeogenesis contributes to hyperglycemia in type 2 diabetes because of impaired 
sensitivity of gluconeogenesis to insulin control. 
 
* Changes in allosteric effectors: Glucagon lowers the level of fructose 2,6-
bisphosphate and  inhibits  phosphofructokinase-1, thus favoring gluconeogenesis over 
glycolysis. 
 
*Covalent modification of enzyme activity: Glucagon elevates intracellular cyclic 
AMP (cAMP) levels and activating cAMP-dependent protein kinase which convert  
pyruvate kinase to its inactive (phosphorylated) form. This decreases the conversion of 
Phospho enol pyruvate (PEP) to pyruvate thus diverting it to the synthesis of glucose. 
 
*Induction of enzyme synthesis: Glucagon increases the transcription of the gene for 
PEP-carboxykinase, thereby increasing the availability of this enzyme as levels of its 
substrate rise during fasting. 
 
B) PROMOTES GLYCOGENOLYSIS: Glycogen causes increased glycogen 
degradation in the liver through covalent modification (phosphorylation) and activation 
of glycogen phosphorylase enzyme. 
 
 
 
C) PROMOTES LIPOLYSIS AND KETOGENESIS : by activation of hormone 
sensitive lipase and inactivation of acetyl CoA carboxylase by covalent modifications. 
The glycerol thus produced is used as a substrate for gluconeogenesis and the free fatty 
acids a source of ketone bodies. 
 
 
 
 
 
 
 
 
 
 
 
              
 
 
 
                                                 
 
 
 
    
                                              EPINEPHRINE30 
 
 Also known as Adrenaline (Adr), is a hormone produced by the adrenal medulla in 
response to sympathetic stimulation. 
 It is known as the hormone for “flight or fight” response. 
 It has α1,α2,β1,β2 and weak β3 action. 
 Stimulus for release include: stress, trauma, cold, exercise and low blood glucose 
levels. 
 
ACTIONS 30:   
 
1. Heart: Adrenaline causes β1 mediated increase in  heart rate, force of contraction. 
Cardiac output and oxygen consumption increase markedly.  
2. Blood vessels: Vasoconstriction( α)  predominates in muco-cutaneous and renal beds. 
Vasodilatation (β2) predominates in skeletal muscles, liver and coronaries. 
3. Blood pressure: slow i.v or s.c injection produces a biphasic response of increase in 
systolic and fall in diastolic BP, as β receptors are more sensitive than α receptors. 
4. Respiration : Adr is a potent bronchodilator (β2)  and decongests the bronchial 
mucosa (α ). 
 
 
 
 
 
 
5. Eye: causes mydriasis by contraction of α1 receptors in the dilator papillae. Reduces 
intra ocular tension. 
6. Skeletal muscle: facilitates neuromuscular transmission by release of acetylcholine 
due to α receptor activation. Increases blood supply to muscle by β2 mediated 
vasodilatation. 
7. Metabolic effects: opposes the actions and release of  insulin 
 Increases blood glucose levels by 
 Inhibition of glycogenesis 
 Stimulation of glycogenolysis in liver (activates glycogen phosphorylase 
enzyme by phosphorylation via c-AMP dependant protein kinases) 
 Reduces the peripheral uptake of glucose in insulin-sensitive tissues 
 Stimulates gluconeogenesis – by increasing availability of substrates 
 Promotes Lipolysis:  
 By phosphorylation and inactivation of acetyl CoA carboxylase enzyme 
necessary for fatty acid synthesis.  
 By activation of hormone sensitive lipase (in adipose tissues), it stimulates the 
breakdown of tri acyl glycerol (TAG) resulting in increased plasma glycerol 
and FFA which are used as substrates for gluconeogenesis and as a source of 
free radicals respectively. 
 
 
 
 Inhibits insulin release by acting on the alpha2 receptors on beta cells of 
pancreas. 
 
 Increases glucagon secretion, irrespective of blood glucose levels in times of 
stress by activating the β2 receptors on the alpha cells of the pancreas. 
 All these actions mediated by epinephrine supplement the effect of glucagon and 
antagonize the effects of insulin thus promoting a state of insulin resistance. 
 
 
                                                 
 
 
 
                                           HYPOGLYCEMIA25 
 
Regular supply of glucose is necessary for tissues like Nervous system and Erythrocytes. 
Hypoglycemia is a medical emergency as transient hypoglycemia can cause cerebral 
dysfunction, while severe and prolonged hypoglycemia can cause brain death. 
The most important hormones to combat hypoglycemia are elevated epinephrine and 
glucagon along with diminished release of insulin. 
 
PHYSIOLOGICAL HORMONAL RESPONSES TO HYPOGLYCEMIA 
 
Humans have two overlapping glucose-regulating systems activated by hypoglycemia:  
 
1)  the alpha cells of pancreas which release glucagon; and 
 2) receptors in the hypothalamus, which respond to abnormally low blood glucose levels.  
 
The hypothalamic glucoreceptors triggers the secretion of epinephrine (mediated by the 
sympathetic nervous system) and the release of adrenocorticotropic hormone (ACTH) 
and growth hormone by the anterior pituitary. 
 
 
 
 Glucagon, epinephrine, cortisol, and growth hormones are sometimes called the 
“counter-regulatory” hormones because each opposes the action of insulin on glucose 
utilization. 
 
1. Glucagon and epinephrine: are most important in the acute or short term 
regulation of blood glucose levels.  Glucagon stimulates hepatic glycogenolysis 
and gluconeogenesis. Epinephrine promotes glycogenolysis and lipolysis, inhibits 
insulin secretion, and inhibits the insulin-mediated uptake of glucose by peripheral 
tissues. 
 
2.  Cortisol and growth hormone: play a role in the long-term management of 
blood glucose metabolism. 
 
SYMPTOMS OF HYPOGLYCEMIA 
 
The symptoms of hypoglycemia can be divided into two categories. 
 
a) Adrenergic symptoms—anxiety, palpitation, sweating, tremors - mediated by 
epinephrine release regulated by the hypothalamus in response to hypoglycemia. 
Usually occurs when the blood glucose falls abruptly.  
 
 
 
b)  Neuroglycopenic symptoms (due to impaired delivery of glucose to the brain - 
impairment of brain function) -  headache, confusion, slurred speech, seizures, 
coma, and death. These often result from a gradual decline in blood glucose which 
deprives the brain of fuel, but fails to trigger an adequate epinephrine response.25 
 
CONSEQUENCES OF RECURRENT HYPOGLYCEMIC ATTACKS 
 
 Hypoglycaemia - associated autonomic failure 
 
 Higher cardiovascular mortality  
 
 Impairment of cognitive function especially in children 
 
 Chronic mood disorders like depression and anxiety 
 
 
   
 
 
 
 
 
                                             
                                           INSULIN RESISTANCE 
 
Insulin resistance refers to suboptimal response of body tissues, especially liver, skeletal 
muscle and fat to physiological amounts of insulin.30 
“Hyperinsulinemia” is the classic indicator of insulin resistance.31 
Insulin resistance plays an important role in pathogenesis and complications of Type 2 
DM. 
 
CONTRIBUTORS TO INSULIN RESISTANCE 
1. Anti insulin hormones: (Diabetogenic hormones) – glucagon, epinephrine, GH, 
cortisol                 
2. Hyperinsulinemia:  repeated stimulation leads to the downregulation of insulin 
receptors (due to enhanced internalization and degradation of the receptor-insulin 
complex).31 
Hyperinsulinemia has also been shown to downregulate insulin-receptor substrates, 
producing an even greater reduction in insulin signaling. 
 
 
3. Stress : acts in multiple ways to promote insulin resistance. The various mechanisms 
include: 
- Stimulation of the sympathetic nervous system - release of epinephrine from the adrenal 
medulla and glucagon from the alpha cells of pancreas – both oppose insulin action.25 
- During stress, there is an increase in free radical (ROS) production due to high 
respiratory oxygen intake and metabolic turnover – producing a state of Oxidative 
stress.32 
 
4.Inflammatory Cytokines: Diabetes is considered as a state of ongoing subclinical 
inflammation. A number of inflammatory cytokines are elevated in diabetes specifically 
TNF- α, IL-6 and IL-1 and Isoprostanes. 
 
The various mechanisms though which inflammatory cytokines mediate insulin 
resistance are 33: 
  inhibition of signaling downstream of the insulin receptor. 
 Induction of iNOS , overproduction of which impairs insulin action on muscle 
and beta cell function. 
 
TNF-α  inhibits  phosphorylation of serine residues of IRS-1 in response to insulin. It 
reduces IRS-1 binding to insulin receptor, thereby inhibiting downstream signaling and 
insulin action. 
 
 
 
IL-6 stimulates C-reactive protein which is positively correlated with insulin resistance, 
obesity, and endothelial dysfunction. 
 
IL-1 inhibits insulin secretion by pancreatic beta cells. 
 
Isoprostanes: are prostaglandin (PG) – like substances produced in vivo by  
non-ezymatic, free radical catalyzed peroxidation of  arachidonic  acid. The best 
characterized among these Isoprostanes are the F2 isoprostanes particulary 8-iso- PGF2α.  
Measurement of Isoprostanes in urine and plasma is considered as a sensitive and reliable 
tool for identifying oxidative stress in vivo. 
 
Isoprostanes are not just biomarkers of oxidative stress but have many biological effects, 
suggesting that they may have a role as pathophysiologic mediators of oxidant injury. 
They mediate their biological actions by acting on prostanoid receptors. Actions include 
34:  
 Induce inflammation and promote atherogenesis through activation of MAP 
kinases .  
 Promote platelet activation , 
 Induce mitogenesis in vascular smooth muscle cells ,  
 Stimulate fibroblast proliferation , and  
 Alter endothelial cell biology by increasing expression of endothelin-1. 
 
 
 Vasoconstriction by inducing synthesis of thromboxane in the endothelium. 
 
PG-F2α has also been shown to induce membrane damage in RBCs resulting in abnormal 
red cell morphology (crenated cells and spherocytes) and subsequent hemolysis, which 
were effectively reversed by Vitamin E, a potent antioxidant.35 
 
5.Oxidative stress and ROS:31 
 
Chronic hyperglycemia leads to increased production of free radicals from the 
mitochondria and Endoplasmic reticulum (ER stress) resulting in oxidative stress. This 
tilts the normal balance between oxidant and antioxidants to favor oxidative damage.  
 
Oxidative stress             activation of serine kinases              ↑ serine phosphorylation of 
the insulin receptor and its substrates                decreased tyrosine phosphorylation of the 
receptor substrates             altered second messenger pathway               decreased 
translocation of glucose transporter (GLUT4)                INSULIN RESISTANCE 
 
 
 
 
 
 
 
 
 
 
SITES OF INSULIN RESISTANCE 31 
 
A) SKELETAL MUSCLE:   Due to reduced insulin receptor substrate-1 (IRS-1)–
associated tyrosine phosphorylation and 1-phosphatidylinositol 3-kinase (PI 3-kinase) 
activity in skeletal muscle. 
 
B) ADIPOSE TISSUE: Proinflammatory adipokines induce systemic insulin resistance 
by direct effects on insulin signaling, downregulation of genes needed for normal 
insulin action and negative regulation of PPARα. 
 
C) LIVER: due to an intrinsic abnormality of insulin signaling in the hepatocyte.  
 
D) HYPOTHALAMUS : Mutation in the hypothalamic LepR-b receptor or decrease in 
circulating levels of leptin has been  associated with  reduced peripheral  insulin 
sensitivity and a state of insulin resistance.36 
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                       OXIDATIVE STRESS 
Biological free radicals are highly unstable molecules which are products of normal 
cellular metabolism. Having  unpaired electrons they react with various organic 
substrates such as lipids, proteins and deoxyribonucleic acid (DNA) and damage cell 
structures leading to Oxidative stress.37 
 
TYPES OF FREE RADICALS:38  
 
1.Reactive oxygen species:  
 
 Superoxide anion radical (O2- )     -  Hydrogen peroxide(H2O2-) - -  
 Hydroxyl radical (OH- )                  - Peroxy radical ( ROO) 
 Hypochlorous acid (HOCl) 
2.Reactive Nitrogen species :  
 
 Peroxynitrite (ONOO-)                     - Nitric oxide (NO.) 
 
 
 
Free radicals produced under physiological conditions are maintained at steady state 
levels by endogenous or exogenous antioxidants which act as free radical scavengers. 
However, when the production of free radicals overwhelms the detoxification capacity of 
the cellular antioxidant system, oxidative stress occurs causing biological damage.39,40 
                 
 
                               
                              OXIDATIVE STRESS IN DIABETES 
 
In diabetics, there is a significant increase in the production of free radicals. This results 
in an imbalance between the oxidants and antioxidants  resulting in oxidative stress that 
leads to activation of stress-sensitive intracellular signaling pathways and formation of 
gene products that cause cellular damage and result in various diabetic complications.41,42. 
 
Hyperglycemia is also directly additive to oxidative stress.  Glucose can autoxidize, 
generating free radicals like hydrogen peroxide and reactive ketoaldehydes.6 
 
 
Oxidative stress in diabetes can cause: 
1. Increased insulin resistance 
 
Elevated glucose and free fatty acids levels in diabetes stimulate the production of free 
radicals.  
These free radicals inhibit the normal tyrosine kinase pathway resulting in insulin 
resistance. 
Oxidative stress             activation of serine kinases              ↑ serine phosphorylation of 
the insulin receptor and its substrates              ↓   tyrosine phosphorylation of the receptor 
substrates             altered second messenger pathway               ↓ translocation of glucose 
transporter (GLUT4)                INSULIN RESISTANCE.43 
 
2. Beta cell failure 
 
β-Cells are particularly susceptible to oxidative stress as they have intrinsically lower 
concentrations of antioxidant enzymes.44 
Excess free radical generation in diabetes further adds to this stress leading to beta cell 
failure. 
 
↑ ROS/RNS             impaired insulin signaling           insulin resistance           ↑ demand 
on β- cells to secrete insulin             β- cell failure 
 
 
 
 
3. Impaired vasodilatation 
 
Oxidative stress is implicated as a cause for abnormal endothelial mediated relaxation of 
blood vessels in diabetes. Experimental studies have shown that ROS inactivate 
endothelium-derived relaxing factor or nitric oxide (NO) and impair endothelium-
dependent relaxation.6 
 
SOURCES OF FREE RADICALS AND ASSOCIATED COMPLICATIONS IN 
DIABETES 
 
1. SORBITOL (POLYOL) PATHWAY 45,47: 
Under normal physiological conditions, Aldose reductase reduces glucose to sorbitol 
using cellular NADPH for the reaction. This enzyme is found in lens, retina, Schwann 
cells of peripheral nerves, kidney, liver, placenta and RBCs.  In liver there is a second 
enzyme called sorbitol dehydrogenase, which oxidizes sorbitol to fructose.   
 
 In diabetes, excess glucose enters into these cells (as they do not require insulin for 
uptake of glucose), resulting in increased production of sorbitol which becomes trapped 
inside the cell. This is exaggerated in cells where levels of sorbitol dehydrogenase is low 
 
 
or absent like lens, retina, kidney, and nerves.  As a result, sorbitol accumulates within 
these cells, producing strong osmotic effects resulting in water retention and cellular 
swelling. This in part explains the pathogenesis of cataract formation, retinopathy, 
neuropathy, and nephropathy seen in diabetics. 
 
Excess sorbitol production depletes cellular NADPH which is required to maintain the 
primary intracellular antioxidant, glutathione, in its reduced state 1, thus predisposing to 
oxidative stress. 
 
 
2. ADVANCED GLYCATION END PRODUCTS (AGEs)  
 
When the blood glucose level is consistently elevated, there is an increase in non-
enzymatic attachment of glucose to amino groups of proteins leading to the formation of 
Advanced Glycation End Products (AGEs).  Once formed, AGEs can cause tissue 
damage by two main mechanisms: 
 
(1) Formation of cross links that alter protein structure and function.  
(2) Interaction of AGE with AGE receptors on the surfaces of various cells such as 
endothelial cells, macrophages, neurons, and smooth-muscle cells results in the  
activation of cell signaling and gene expression that induce oxidative stress and 
inflammation.46,47 
 
 
 
In diabetes, AGEs have been implicated in the pathogenesis of retinopathy, nephropathy, 
atherosclerosis, cardiomyopathy, diastolic dysfunction and systolic hypertension.48 
 
3.  PROTEIN KINASE C (PKC) ACTIVATION 49,50 
Protein kinases such as PKA, PKC are intra cellular signaling molecules. They   
phosphorylate  serine and threonine residues in target proteins.Physiologically the most 
important activator of PKC is Diacylglycerol (DAG) 
In diabetes, hyperglycemia causes the activation of PKC by two major pathways: 
- Enhanced de novo synthesis of diacylglycerol (DAG) from glucose.  
- Interaction between AGE’s and their cell-surface receptors can result in 
enhanced activity of certain PKC isoforms . 
 
PKC seems to regulate diabetic complications on multiple levels by activation of 
NADPH oxidase, phospholipase A2, endothelin-1, Vascular endothelial growth factor, 
Transforming growth factor-β, and  NF-KB. It also inhibits NO synthesis by inhibiting 
NO synthase enzyme.  
 
Thus activation of PKC is related to hyperplasia of smooth muscle cells, vasoconstriction 
and enhanced synthesis of extracellular matrix proteins which play an important role in 
the onset and progression of vascular dysfunction in diabetes.51,52 
 
 
                                              
 
                                               RED BLOOD CELL 
 
Red blood cells (RBCs) or Erythrocytes are formed within the bone marrow from 
Pluripotent hemopoietic stem cells. Their red color is due to the presence of the coloring 
pigment called hemoglobin. 
The process of the origin, development and maturation of erythrocytes is known as 
Erythropoiesis.53 
 
 
STAGES OF ERYTHROPOIESIS 54 
Pluripotent hemopoietic stem cells differentiate into Colony forming units- Erythrocyte 
(CFU-E), which then pass through the following stages to form the mature red blood cell. 
 
 
 
             PLURIPOTENT 
HEMOPOIETIC STEM CELLS 
 
 
 
 Proerythroblast: first cell derived from CFU–E. 
Contains large nucleus with nucleoli. Hemoglobin 
synthesis starts. Size 20 microns. 
 
 Early Normoblast: nucleoli disappear and 
condensation of chromatin occurs. Size 15 
microns.  
 
 Intermediate Normoblast: chromatin shows 
further condensation and hemoglobin starts 
appearing. Size is 10 -12 microns.  
 
 
 Late Normoblast: Nucleus disintegrates and 
disappears (a process known as Pyknosis). 
Hemoglobin quantity increases. Size 8-10 microns 
 
 
 Reticulocyte: also known as immature RBC. 
Cytoplasm contains the reticular network formed 
by remnants of disintegrated organelles (golgi 
apparatus, mitochondria etc). During this stage, 
the cells enter circulation by diapedesis. 
 
 Matured Erythrocyte: reticulum disappears and 
cells attain a biconcave shape. Size 7-8 microns.  
 
 
 
 
. 
..  
           
        Average RBC count is 5.4 million/μL in men and 4.8 million/μL in women. 55 Their 
main function is to transport oxygen from lungs to tissues and remove carbon dioxide 
from the tissues (in the form of bicarbonate ion).56 
Normal life span of RBC is about 120 days.  
Main site of destruction is in the reticulo-endothelial system of the liver and spleen, 
particularly the macrophages of spleen.57 
 
 
 
 
  STRUCTURE OF RBC  
 
 The red blood cell membrane has three basic components, lipid bilayer, transmembrane 
(integral) proteins and a cytoskeletal network.  
 The lipid bilayer is made up of 60% phospholipids, 30% cholesterol and 10% 
glycolipids. Cholesterol provides flexibility and stability to the red cell membrane.   
 The sub-membrane cytoskeleton of the RBC consists of several proteins like spectrin, 
ankyrin, protein 4.1 and actin that form a quasi-two-dimentional meshwork under the 
lipid layer. Its biconcave shape is maintained by these proteins especially the spectrin 
network and the lipid bilayer.12 This characteristic shape allows it to squeeze through 
narrow splenic capillaries without getting damaged. 
RBCs lack a nucleus (no DNA) and organelles like mitochondria, ribosome and 
endoplasmic reticulum.58 Its cytoplasm contains haemoglobin (major protein), enzymes 
for glycolytic (eg:pyruvate kinase) and HMP shunt (eg:G6PDenzyme) pathway and 
endogenous antioxidants like reduced glutathione, Vitamin C and Vitamin E. 
 
 
 
 
 
 
ERTHROCYTE METABOLISM 
Glycolysis is the only source of ATP production in a mature RBC.59  
Erythrocytes lack mitochondria, therefore glycolysis always terminates in lactate 
formation as the subsequent reactions for pyruvate oxidation are absent.57 
Glucose entry into RBCs is independent of insulin. Glucose enters RBCs by Na+-  
independent facilitated diffusion via GLUT-1. 
 90% of the entered glucose enters glycolysis for ATP production and the remaining 
10% glucose enters into the hexose monophosphate (HMP) shunt pathway to generate 
NADPH using G6PD (glucose 6-phosphate dehydrogenase) enzyme. This NADPH is 
used by RBCs to reduce glutathione, its primary intracellular antioxidant.12 
                      
              REASONS FOR HEMOLYTIC ANEMIA IN DIABETES 
 
Diabetes is a state of excess free radical production. Chronic stress plays a critical role, 
and along with hyperglycemia, they increase the generation of Reactive oxygen species 
(ROS) from mitochondria and endoplasmic reticulum leading to Oxidative stress.60,61 
 
In diabetes there is an increased flux of glucose through the sorbitol pathway which 
results in the depletion of NADPH.  This NADPH is essential in RBCs for regenerating 
reduced glutathione (GSH), the prime antioxidant protecting the RBCs from oxidative 
 
 
damage and necessary for maintaining the cellular glutathione pool. Furthermore, ROS 
induced cell membrane damage allows the available GSH to pass through the membrane 
causing depletion of GSH in the cytoplasm of the RBC. As the mature erythrocyte lacks a 
nucleus and ribosome it cannot regenerate GSH or synthesize new protein, thus making it 
vulnerable to oxidative damage.62 
 
The free radicals generated in diabetes stimulate the release of a number of inflammatory 
cytokines like TNF-alpha, IL-1 & 6 and Isoprostanes (PG-F2α).
35 These cytokines further 
increase the generation of ROS, a viscious cycle results, worsening oxidative damage to 
cells. 
 
Red blood cells are especially prone to this oxidative damage as they contain high levels 
of hemoglobin and oxygen and are the first cells to be affected by adverse conditions. 
Since RBCs lack mitochondria, glycolysis is the only way of generating ATP which is 
required to maintain its characteristic biconcave shape and flexibility. In the absence of 
adequate ATP, the RBC membrane loses integrity and is prone to lysis.63 
 
Glucagon plays an important role in the pathogenesis of diabetes. Stress activates the 
sympathetic nervous system which enhances the release of glucagon. Glucagon causes 
hyperglycemia which in turn enhances free radical generation and oxidative stress. 
Glucagon also inactivates Pyurvate kinase, an enzyme of the glycolytic pathway, thereby 
 
 
reducing production of ATP.63 Lack of sufficient ATP and free radical mediated injury 
damages RBC membrane, increasing its fragility and leading to hemolytic anemia.   
 
ROS induced oxidation of membrane proteins make red cells rigid and less deformable, 
allowing them to be removed by the macrophages in the reticuloendothelial cells of 
spleen. Oxidation of sulphhydryl groups in hemoglobin leads to the formation of 
disulfide cross-linkages between adjacent globin chains causing a distortion of 
hemoglobin structure and forming denatured visible precipitates called “Heinz bodies” 
which attach to the red cell membrane and excised by the macrophages of the spleen.62 
   
 Structural changes in the RBC due to oxidative damage include:   
1. Irregularly contracted and Crenated cells – Due to altered cell membrane 
integrity64 
2. Reticulocytes – immediate precursors of mature red blood cells containing a 
reticulum(made of disintegrated cell organelles).54 
3. Heinz bodies –  insoluble aggregates of  oxidized haemoglobin 65 
  4.  Bite cells   - Remaining cells after removal of Heinz bodies by spleen 66 
  5. Spherocytes -  Smaller and denser than normal RBC with spheroidal structure67        
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                                                           ANTIOXIDANTS 
 
DEFINITION: 
An antioxidant is a stable molecule that interacts and neutralizes free radicals preventing 
them from causing tissue damage.68 
 
CLASSIFICATION 
The various Antioxidants are categorised into 44: 
 
a) Enzymatic antioxidants:  Glutathione reductase, Superoxide dismutase, 
Glutathione peroxidase, Catalase. 
 
b) Non-enzymatic antioxidants: α lipoic acid, Vitamins C and E, bioflavinoids 
coenzyme Q , antioxidant minerals (copper ,selenium, zinc and manganese). 
 
 
 
 
 
                                 ASCORBIC ACID (VITAMIN C) 
It is a water soluble vitamin and the major antioxidant in plasma and tissues.  
 STRUCTURE:                 
                                                                                        
ACTIVE FORM: 
-  Dehydroascorbic acid (DHA)                       -  Ascorbic acid (AA) 69 
 
DIETARY SOURCES: 
PLANT SOURCES: 
-Indian goose berry        - Chilli pepper           - Guava                       - Black currant            
- Red pepper                   - Lemon                      -Orange                       - Broccoli 
 
ANIMAL SOURCES:    - Lamb brain      - Calf liver     - Chicken liver, kidney69 
 
 
 
 
BIOSYNTHESIS 
-Vitamin C is an essential nutrient for human beings as they lack an enzyme required 
for its synthesis.69 
-It is not stored in any organ in the body. 
-Plants and animals can synthesize their own vitamin C. 
 
PHARMACOKINETICS 
-Absorption takes place through simple diffusion and active transport 
-High intake reduces absorption 70 
 
FUNCTIONAL ROLE 68,69 
1. ANTIOXIDANT 
 
It serves as an antioxidant due to its ability to react with free radicals and undergo a 
single-electron oxidation process to form ascorbyl radical, a poorly reactive intermediate 
which disproportionates to ascorbate and dehydroascorbate.69 
 First line of defense against ROS in plasma, interstitial fluids and soluble phases of 
cells. 
 
 
 Protects Lipid, DNA and Nitric oxide from oxidation. 
 Regenerates the metabolically active (reduced) form of Vitamin E  (tocopherol form 
tocopheroxyl radical) – synergistic action 
 Protects Glutathione in its reduced form by quenching of oxidants. 
 
IN DIABETES 
 Reduces insulin resistance by inhibiting oxidant induced serine phosphorylation of 
IRS and enhancing tyrosine kinase activity, thereby improving downstream insulin 
signal transduction. 
 Regenerates other antioxidants, helps in maintaining antioxidant pool. 
 Reduces glycosylation of plasma proteins suggesting a role in preventing diabetic 
complications71 
 Reduces sorbitol accumulation within erythrocytes by inhibiting aldose reductase 
activity.72 
 
2. ENZYMATIC CO-SUBSTRATE FUNCIONS 
 
 Helps in synthesis of collagen by hydroxylation of prolyl and lysyl residues.73 
 Catalyses ferrochelatase and incorporates iron into protoporphyrin IX to form heme 
 Acts as co-factor in synthesis of carnitine 
 
 
 Serves as an electron donor in hydroxylation reaction of dopamine to form 
norepinephrine.73 
 
3. CARDIOVASCULAR HEALTH 
 
 Anti-atherogenic effect by reducing oxidation of LDL. 
 Improves exercise tolerance by its effect on reducing endothelial dysfunction 74 
(Protects nitric oxide (NO), a major vasodilator from oxidation). 
 
4. EFFECT ON BLOOD PRESSURE  
 Protecting NO from inactivation by ROS and promoting vasodilatation. 
 Improving arterial stiffness by protecting cell membrane pumps from oxidative 
damage and promoting ion flux. 
 Modulating the autonomic nervous system by restoring sympathovagal balance and 
improving spontaneous baroreceptor sensitivity.75 
 These effects result in lowering of blood pressure. 
 
 
5. PROMOTION OF IRON BIOAVAILABILITY 
 
 Increases iron availability in foods due to increased enteric absorption. 
 
 
 Also promotes utilization of heme iron by enhanced incorporation into Ferritin. 
 
6. METABOLISM OF CHOLESTEROL 
 Cholesterol is routinely converted into bile acids in the body. For this transformation 
reaction, hydroxyl group is incorporated into cholesterol nucleus with the help of 
vitamin C.  
 By increasing the expression of LDL receptor in the liver it helps in LDL 
degradation.76 
      These mechanisms help reduces serum cholesterol levels. 
 
7. IMMUNITY   
 It modulates Phagocytic activity, Lymphocytes and cytokine production, Interferon 
production,T cell gene expression and  synthesis of  IgG and IgM antibodies 69 
 
8. ANTI INFLAMMATORY ACTION 
 Supresses the production of 8isoPGF2α, the first identified isoprostane produced by 
non-enzymatic free radical induced lipid peroxidation. 
 Reduces biomarkers of inflammation (c-reactive protein) and endothelial dysfunction 
(tissue plasminogen activator) 
 
 
 
9. CATARACT 
 Protects lens from photo-oxidative effects of Ultraviolet light. 
 Prevents development of cataract by reducing sorbitol accumulation in the lens. 
 
10. CANCER 
 Vitamin C is a potent inhibitor of nitrosamine-induced carcinogenesis, by functioning 
as a nitrite scavenger.69 
 
11. MISCELLANEOUS 
 Improves Bone health                             * Promotes wound healing 
 
DEFICIENCY 69 
-Scurvy                                     -Weak bones 
-Bleeding tendencies               - Delayed wound healing 
-Teeth malformation              - Decreased iron content of body 
- Painful joints                       - Malaise                                - Depression 
 
 
 
 
 
ADVERSE EFFECTS 
(High dose >2g/day) 
 Mild GI upset 
 Headache 
 Sleep disturbances 
 Oxalate stones in kidney ( dose >4g/day) 77 
USES 77 
 Scurvy – prevention and treatment  
 Anemia 
 Non healing leg ulcer 
 Bed sores 
 Common cold 
 Methaemoglobinemia- as a reducing agent. 
 To acidify urine in urinary tract infections 78 
 
                                               
 
 
 
 
                                                    VITAMIN E 
 
 Fat soluble vitamin 
 Vitamin E available as eight forms: Tocopherol -4 ,tocotrienols -4 
 Most common active form is α-tocopherol 
CHEMICAL STRUCTURE 
 
 
SOURCES 
-Wheat germ oil                - Rice bran oil               -Soyabean oil               - Nuts                                    
- Sunflower oil                  - Safflower oil              - Fish                            - Egg yolk                                          
- Cereals                            - Spinach                      -Green leafy vegetables 69 
 
 
 
Has a chromanol ring and C-6 
hydroxyl group (which donates 
hydrogen for reducing free radicals) 
and hydrophobic side chain (for 
penetrating biological membranes)79 
 
 
PHARMACOKINETIC PARAMETERS 
 Primarily absorbed in medial small intestine  
 Does not have a specific carrier in plasma and is rapidly transported from 
chylomicrons to plasma lipoproteins or directly to tissues 
 Metabolized in liver by oxidation (CYP enzymes) and excreted in urine and bile 
 In non-adipose cells, vitamin E is localized almost exclusively in membranes.80 
 
FUNCTIONAL ROLE 
 
1. ANTI OXIDANT 
Vitamin E is the major antioxidant in membranes and has membrane stabilizing action. 
It gets incorporated into the phospholipid bilayer and  protects the PUFAs of the cellular 
membranes from free radical induced oxidative damage.81 In serving its antioxidant 
function, it gets converted to tocopheroxyl radical which is unreactive and thus it stops 
the destructive propagative cycle of oxidative damage. It is regenerated to its active form 
by Vitamin C. 
 
 
 
 
 
IN DIABETES 
 In Diabetes due to oxidative stress there is increased lipid peroxidation, particularly in 
erythrocytes which leads to their premature lysis. Vitamin E (synergestic with 
Vitamin C) prevents oxidation of PUFAs in the cell membrane, thereby maintaining 
integrity of the RBC membrane, reducing fragility and oxidative stress induced 
hemolysis.  
 Vitamin E may have a role as an erythropoietic factor, thus improving anemia82 
 Lowers urinary and serum F2 isoprostanes levels in diabetics, an important marker of 
oxidative stress.83 
 Reduces insulin resistance by increasing tyrosine kinase activity.  
 
2. IMMUNITY  
 Modulates T cell function, stimulates production of lymphocytes and antibodies. 
Promotes Phagocytosis.81 
 
3. ANTIINFLAMMATORY ACTION 
 Inhibits Phospholipase A2 activity, thus preventing release of Arachidonic acid and 
subsequent generation of Prostaglandins and Leukotrienes. 
 Inhibit release of proinflammatory cytokines from activated macrophages.81 
 
4. CARDIOVASCULAR HEALTH 
 
 
 Prevents LDL oxidation and subsequent atherosclerotic plaque formation.84 
 Reduces platelet  aggregation85 
 
5. ANALGESIC ACTION 
 Reduces central pain processing  by suppression of  nitric oxide (NO lowers the 
threshold of nociceptors thus facilitating pain transmission pathway) 86 
 
6. ANTICARCINOGENESIS 
 Selectively stimulate apoptosis in certain neoplastic cells by receptor induced caspase 
-8 and -3 activation in some cancer cells and caspase -9 activation in others.84 
 
7. CATARACTS 
 Direct antioxidant effect or indirect antioxidant effect in maintaining lens glutathione 
in reduced state, it has shown to lower risk of cataract formation.81 
 
DEFICIENCY SYMPTOMS:81 
*Loss of appetite                                    *Spinocerebellar Ataxia  
 *Peripheral neuropathy                           *Decreased immunity 
 *Retinopathy                                          *RBC hemolysis, anemia         
 *Myopathies 87 
 
 
 
ADVERSE DRUG REACTIONS 
It is viewed as one of the least toxic vitamins with doses upto 400 IU/day tolerated well. 
High dose (>2000 mg/day) can produce: 
- Headache                           - Double vision 
- Muscle weakness               - GI upset, nausea               - Creatinuria  
- Bleeding tendency: due to reduced Vitamin K – dependant carboxylase 
activity. 88 
  USES 88 
 Diabetes mellitus 
 Haemolytic anemia of prematurity 
 Chronic hemolysis in G6PD deficiency 
 Acanthocytosis  
 Intermittent claudication 
 Benign breast tumour 
 Nocturnal leg cramps 
 Sterility 
 Atherosclerosis 
 Parkinson’s disease 
 Alzeihmer’s disease. 
 
 
 
 
AIM AND             
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                                          AIM AND OBJECTIVE 
 
AIM:  
To study the efficacy of Vitamin E and Vitamin C in Type 2 Diabetes Mellitus. 
 
OBJECTIVES: 
 
PRIMARY OBJECTIVE: 
To study red blood cell morphology in early Type 2 Diabetes patients as a marker of 
oxidative stress and the efficacy of Antioxidants such as Vitamin C and E as an add on 
therapy to standard treatment. 
 
SECONDARY OBJECTIVE: 
 Improvement in glycemic control and haemoglobin level. 
 
 
 
 
 
 
 
METHODOLOGY 
 
 
                                      
 
 
 
 
 
 
 
 
 
                                                    METHODOLOGY 
 
STUDY DESIGN:  
Randomized, Open label, Comparative Pilot study 
 
STUDY POPULATION:  
Adult patients with early Type 2 Diabetes Mellitus attending the diabetic outpatient 
department. 
 
STUDY CENTER:  
Institute of Diabetology, Madras medical college & Rajiv Gandhi Government General 
Hospital, Chennai. 
 
STUDY PERIOD:  
January 2015 – December 2015 
 
SAMPLE SIZE:  
60 patients (30 patients in control group and 30 patients in study group) 
 
STUDY DURATION:  
8 weeks study period and 4 weeks follow up per patient 
 
 
 
 ELIGIBILITY CRITERIA 
INCLUSION CRITERIA: 
 Age: 30-70 years 
 Sex-both genders 
 Patients diagnosed with Type 2 Diabetes Mellitus within 2 yrs 
 Patients on metformin monotherapy. 
 Patients willing to give written informed consent 
 
EXCLUSION CRITERIA: 
 Patients with Type 1 Diabetes Mellitus 
 Current or ex smokers 
 Pregnant and lactating women 
 Patients with co-existing liver disease, heart disease, renal disease or malignancy 
 Patients on any lipid lowering drugs 
 Patients with any diagnosed hematological disorder 
 Patient enrolled in any other study 
 
 
 
 
 STUDY PROCEDURE 
 
The study was conducted after obtaining approval from the Institutional Ethics 
Committee, Madras Medical College and was done in accordance with Declaration 
of Helsinki and Good Clinical Practice (GCP) guidelines.  Patients diagnosed with 
Type 2 Diabetes Mellitus within the last 2 years on metformin monotherapy were 
recruited from the outpatient department of the Institute of Diabetology, Madras 
Medical College & Rajiv Gandhi Government General Hospital. The purpose 
procedures and benefits of the study were explained to them. Written informed 
consent was obtained from the subjects who were willing to participate in the trial 
in the prescribed format in regional language prior to performance of any study 
related procedure. If the patient was illiterate, left thumb impression in the presence 
of an impartial witness was taken.  
The demographic details of the patients was obtained and recorded. Patients were 
screened by History, General & Systemic examinations and Lab investigations. 
Patients who fulfilled the inclusion and exclusion criteria were enrolled and 
randomized to either the study group or control group. 
 
 
 
 
 
 
The following lab investigations were performed during screening. 
- Fasting blood sugar                                     - Haemoglobin  
- Total Red blood cell count                          - Liver function tests 
- Renal function tests 
 
 
RECRUITMENT:  
 
 102 patients were screened and 30 patients in each group (control and study 
groups) who fulfilled the inclusion and exclusion criteria were recruited into the 
study.  
 No drop-out of patients occurred  in either of the groups  
 
RANDOMIZATION 
 
The enrolled patients were randomized by simple randomization into control and study 
group and received the respective therapies. 
 
 
 
 
 
 
 
 TREATMENT PLAN 
 
GROUP A  - Control group(n=30): patients received standard treatment. 
Standard treatment: 
 Tablet Metformin 500 mg twice daily 
 
GROUP B  - Study group (n=30): patients received standard treatment plus one tablet 
of Vitamin C -500mg and one capsule of Vitamin E -400IU each once daily. 
The patients received the study medication for 4 weeks at a time and were asked to 
review at the end of 4 weeks and 8 weeks with the empty blister pack to check 
compliance. 
 
 
 
 
 
 
 
 
 
 
 
STUDY FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCREENING 
n = 102 
Complete medical 
history, Clinical 
examination, 
Biochemical 
investigation 
STATISTICAL ANALYSIS 
RANDOMIZED 
ENROLLED 
             n = 60 
n 
 
 
EXCLUDED 
       n = 42 
 
CONTROL GROUP 
n=30 
STUDY GROUP 
n=30 
STANDARD TREATMENT +TEST 
DRUG 
T. Metformin 500 mg BD 
            C.Vitamin E 400IU OD  
            T.Vitamin C 500mg OD 
STANDARD TREATMENT  
 T. Metformin 500 mg BD 
 
 
TREATMENT PERIOD – 8 weeks 
FOLLOW UP - 4 weeks 
 
 
 
                                        SCHEDULED VISITS 
SCREENING: 
 Written Informed consent obtained 
 Demographic details obtained 
 Medical history obtained 
 General & systemic examination done 
 Laboratory investigations done 
 Enrolment done. 
 
Visit 1  
 Randomization done 
 Vital signs recorded 
 RBC morphology studied 
 Fasting blood sugar, haemoglobin and RBC count measured 
 Study medications issued for 4 weeks  
 Instructed  to return empty strips during subsequent visit 
 Asked to report any adverse event, if any occurs. 
 
 
 
 
 
 
Visit 2 (end of 4 weeks) 
 Vital signs recorded 
 Asked for return of empty strips to assess compliance 
 Adverse events recorded, if any 
 RBC morphology studied 
 Fasting blood sugar, haemoglobin and RBC count measured 
 Study medications issued for another 4 weeks  
 
Visit 3 (end of 8 weeks) 
 Vital signs recorded. 
 RBC morphology studied 
 Fasting blood sugar, haemoglobin and RBC count measured  
 Adverse events recorded, if any 
 
Visit 4 (end of 12 weeks) 
 Vital signs recorded 
 Adverse events recorded, if any 
 RBC morphology studied 
 Fasting blood sugar, haemoglobin and RBC count measured       
 
 
 
 
 
                       ASSESSMENT 
 
   I. Morphological changes in RBCs: 1ml of the patient’s blood was centrifuged at 3000 
rpm for 5 minutes. The supernatant was discarded and the packed cells diluted with equal 
volume of 0.9% normal saline and centrifuged again. The supernatant was again 
discarded and the packed cells reconstituted as 10% v/v suspension with 0.9% normal 
saline and a drop of this suspension was put on a glass slide under a cover slip and 
studied under high power microscope. 
Under the high power microscope, a central field was selected. 100 RBC’s were veiwed 
and the number of Crenated RBCs with Heinz bodies were counted for each patient in 
both the groups at each visit and recorded as a percentage.  
 
 Glycemic control- based on fasting blood sugar levels 
 
 Hemoglobin levels and RBC count – was recorded at each visit 
Differences in the counts before and after treatment in the both the groups were recorded. 
 
 
 
 
 
Lab investigations: 
The following additional investigations were repeated for the patients at the end of 8 
weeks of treatment. 
 Blood urea 
 Serum creatinine 
 Liver function tests 
 
 
INSTRUCTION TO PATIENTS 
 
The patients were instructed clearly regarding the regular intake of the medicines. They 
were given proper advice to report for assessment and drug receiving. They were 
counseled to report if any acute complaints, reactions occur. 
 
FOLLOW UP 
The patients were followed up for a post treatment period of 4 weeks, without the study 
drug for the assessment of vitals, Hemoglobin, RBC count and RBC morphology. 
After the completion of 12 weeks of study period, the patients were provided appropriate 
medical care at Institute of Diabetology, Rajiv Gandhi Government General Hospital, 
Chennai. 
 
 
 
 ADVERSE EVENTS 
 
Any adverse event reported by the patient or observed by the physician during the study 
was recorded. The onset of adverse event, causal relationship to the study drug and action 
taken was recorded. Appropriate medical care was provided.        
                                 
 WITHDRAWAL 
 
During the study period the subject was allowed to withdraw his/her voluntary consent 
and opt out of study. Similarly at the discretion of the investigator, the subjects were 
withdrawn from the study if any serious adverse event reported by the patient or observed 
by the physician. 
 
 
 
 
 
 
 
 STATISTICAL ANALYSIS 
The obtained data was analyzed statistically.  
Distribution of age was analyzed using one way ANOVA and Sex distribution was 
analyzed by Pearson chi- square test. 
The difference within the groups in hemoglobin level, RBC count, RBC morphology, 
Systolic and Diastolic blood pressure was analyzed using students paired t-test. Similarly 
the difference between the control and test groups was analyzed using independent t-test.  
The biochemical investigations were performed at baseline and at the end of 8 weeks. 
The differences within the groups before and after treatment were analyzed using 
student’s paired t- test.  
Statistical analysis was done using SPSS vs 20. 
P value <0.05 was considered to be statistically significant. 
 
 
 
 
 
 
 
 
 
 
            RESULTS 
 
 
 
 
 
 
 
 
 
 
                         TABLE 1: MEAN AGE DISTRIBUTION 
GROUPS n (No. of 
patients) 
MEAN AGE 
 (in years) 
SD p VALUE 
CONTROL 30 48.33 9.19      0.844 
STUDY 30 47.87 9.06 
Table 1 – shows the mean age distribution of patients among control and study groups. 
The mean age of patients in control group is 48.33 and in the study group is 47.87 (p = 
0.844), indicating that there is no significant difference in age between the two groups. 
                         FIGURE 1: MEAN AGE DISTRIBUTION 
 
  Fig 1 is a graphical representation of Table 1. 
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                                TABLE 2: GENDER DISTRIBUTION 
 
Table 2 - shows the distribution of male and female patients in the two groups 
In control group, 10 patients are male (33%) and 20 patients are female (67%) and in 
study group, 11 patients are male (37%) and 19 patients are female (63%). There is no 
significant difference in sex distribution. 
 
 
 
 
 
    SEX DISTRIBUTION 
                                 
                                 GROUPS 
 
        CONTROL 
 
              STUDY 
        n 
 
       %          n              % 
                 MALE        10 33% 11 37% 
FEMALE 20 67% 19 63% 
TOTAL NO. OF 
PATIENTS 
30 100% 30 100% 
 
 
                           
                                 FIGURE 2: GENDER DISTRIBUTION 
 
 
    Fig 2 is a graphical representation of Table 2 
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                TABLE 3: MEAN DURATION OF DIABETES (MONTHS) 
Table 3 – shows the mean duration of diabetes among the patients in the control and    
study group. 
The mean duration of diabetes in patients in the control group is 11.4 months and in the 
study group is 9.13 months.  p = 0.175 indicating that there is no significant difference in 
the mean duration of diabetes between the two groups. 
                  FIGURE 3: MEAN DURATION OF DIABETES (MONTHS) 
 
   Fig 3 is a graphical representation of Table 3 
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                        TABLE 4 : MEAN FASTING BLOOD GLUCOSE (mg/dl) 
 
Table 4- shows the mean fasting blood glucose levels in control and study groups. 
On comparing the two groups, 
There is a statistically significant reduction within the control group (p = 0.030) and 
within the study group (p=0.001) in fasting blood glucose levels at the end of 8 weeks. 
 The difference between the control and study groups on day 0 ( p = 0.762) is 
insignificant  but and at the end of 8 weeks (p=0.001) there is a statistically significant 
reduction in fasting blood glucose level in study group compared to the control group. 
           
 
 
GROUPS 
DAY 0 AT THE END OF 8 
WEEKS 
p value 
MEAN  
(mg/dl) 
SD MEAN 
(mg/dl) 
SD 
CONTROL 185.2 57.66 144.8 29.58 
 
0.030 
STUDY 181.6 27.98 117.3 15.77 0.001 
p value 0.762 0.001 
 
 
 
                FIGURE 4 : MEAN FASTING BLOOD GLUCOSE (mg/dl) 
 
 
    Fig 4 is a graphical representation of Table 4 
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TABLE 5 – MEAN PERCENTAGE OF CRENATED RBCs WITH HEINZ  
BODIES (%) 
                                                                        
Table 5 - shows the mean percentage of crenated red blood cells with Heinz bodies in the 
control and study groups 
On comparing the two groups, 
There is no statistically significant change within the control group (p =0.051) but the 
study group shows significant reduction in the % of crenated RBCs at the end of 8 weeks 
(p=0.001).  
There is no significant difference between the control and study group on day 0 ( p = 
0.256)  But at the end of 8 weeks study group shows a significant reduction in the % of 
crenated RBCs compared to control group (p=0.001) . 
     
 
GROUPS 
DAY 0 AT THE END OF 8 
WEEKS 
p value 
MEAN  
(%) 
SD MEAN 
(%) 
SD 
CONTROL 80.83 13.06 76.87 12.79 
     0.051 
STUDY 84.67 12.82 6.93 2.16 0.001 
p value 0.256 0.001 
 
 
 
FIGURE 5: MEAN PERCENTAGE OF CRENATED RBCs WITH HEINZ    
BODIES (%) 
                                      
 
      Fig 5 is a graphical representation of Table 5. 
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                        MORPHOLOGY OF RBCs BEFORE TREATMENT 
 
                    
                      MORPHOLOGY OF RBCs AFTER TREATMENT 
     
 
 
                    MORPHOLOGY OF RBCs BEFORE TREATMENT 
   
 
MORPHOLOGY OF RBCs AFTER TREATMENT 
      
 
 
                  
                      TABLE 6A: MEAN HAEMOGLOBIN(gm%) 
 
Table 6A - shows the mean hemoglobin values of patients in the control and study group. 
On comparing the two groups, 
 There is no statistically significant change within the control group  
(p =0.690) but the study group shows significant increase in mean haemoglobin at the 
end of 8 weeks (p=0.001). 
 There is no significant difference between the control and study group on day0 (p = 
0.633). But at the end of 8 weeks, the study group shows a significant increase in mean 
haemoglobin compared to the control group (p=0.003). 
 
 
GROUPS 
DAY 0 AT THE END OF 8 
WEEKS 
p value 
MEAN  
(gm%) 
SD MEAN 
(gm%) 
SD 
CONTROL 10.367 1.311 10.343 1.30 
 
0.690 
STUDY 10.190 1.534 11.450 1.462 0.001 
p value 0.633 0.003  
 
 
 
 
FIGURE 6A: MEAN HAEMOGLOBIN(gm%)  
 
 
 Fig 6A is a graphical representation of Table 6A 
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                  TABLE 6B – NUMBER (%) OF PATIENTS WITH ANEMIA 
HEMOGLOBIN (g/%)     CONTROL 
       (n=30) 
      STUDY 
      (n = 30) 
<12 gm% (ANEMIC)        24 (80%)       25 (83%) 
>12 gm%(NOT ANEMIC)        6 (20%)        5 (17%) 
 
Table 6B – shows the number (%) of patients with anemia (Hb <12gm%).  
Majority of the patients in the control group(80%) and study group(83%) had anemia 
with hemoglobin of less than 12 gm%. 
FIGURE 6B: NUMBER OF PATIENTS WITH ANEMIA 
 
Figure 6B is a graphical representation of Table 6B 
 
0
5
10
15
20
25
30
CONTROL STUDY
24 25 
6 5 
N
U
M
B
E
R
 O
F
 P
A
T
IE
N
T
S
 
Hb>12
Hb<12
 
 
TABLE 7: MEAN RED BLOOD CELL(RBC) COUNT(millions/μL) 
 
Table 7 - shows the mean Red blood cell (RBC) count in patients of the control and 
study groups 
On comparing the two groups, 
There is no statistically significant change within the control group  
(p =0.624) but the study group shows a significant increase in RBC count at the end of 8 
weeks (p=0.001). 
 There is no significant difference between the control and study groups on day 0 (p = 
0.730). But at the end of 8 weeks the study group shows a significant increase in the RBC 
count compared to the control group (p=0.003). 
 
 
         GROUPS 
DAY 0 AT THE END OF 8 
WEEKS 
p 
value 
MEAN  
(millions/μL) 
SD MEAN 
(millions/μL) 
SD 
CONTROL 3.523 0.454 3.512 0.451 
 
0.624 
STUDY 3.48 0.514 3.886 0.489 0.001 
p value 0.730 0.003  
 
 
 
FIGURE 7: MEAN RED BLOOD CELL COUNT(millions/μL) 
 
 
 
  Fig 7 is a graphical representation of Table 7 
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TABLE 8 :  MEAN SYSTOLIC BLOOD PRESSURE(mmHg) 
 
Table 8 - shows the mean systolic blood pressure in control and study groups 
On comparing the two groups, 
There is no statistically significant change within the control group  
(p =0.436) but the study group shows significant reduction in mean systolic blood 
pressure at the end of 8 weeks (p=0.027). 
There is no significant difference between the control and study group on day 0 (p = 
0.330)  But at the end of 8 weeks there is significant reduction in systolic blood pressure 
in study group compared to control group (p=0.042). 
                
 
       GROUPS 
DAY 0 AT THE END OF 8 
WEEKS 
p value 
MEAN  
(mm Hg) 
SD MEAN 
(mm Hg) 
SD 
CONTROL 124.2 10.691 126.3 9.681 
0.436 
STUDY 126.8 9.792 120.6 11.34 0.027 
p value 0.330 0.042  
 
 
             
 
FIGURE 8: MEAN SYSTOLIC BLOOD PRESSURE (mmHg) 
 
 
 
   Fig 8 is a graphical representation of Table 8 
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TABLE 9 : MEAN DIASTOLIC BLOOD PRESSURE (mmHg) 
 
Table 9 - shows the mean diastolic blood pressure in control and study groups. 
On comparing the two groups, 
There is no statistically significant change within the control group 
 ( p =0.908). However there is significant reduction in the mean diastolic blood pressure 
in the study group (p=0.014). 
The difference between the control and study groups on day 0 (p =0.669) is not 
significant but there is significant difference in the reduction of diastolic blood pressure 
at the end of 8 weeks between control and study groups (p=0.035). 
 
GROUPS 
DAY 0 AT THE END OF 8 
WEEKS 
p value 
MEAN BP 
(mm Hg) 
SD MEAN BP 
(mm Hg) 
SD 
CONTROL 80.6 6.790 80.4 6.526 
 0.908 
STUDY 81.4 7.596 76.4 7.762 
 0.014 
p value 0.669 0.035  
 
 
      
 
FIGURE 9: MEAN DIASTOLIC BLOOD PRESSURE(mmHg) 
 
 
      Fig 9 is a graphical representation of Table 9 
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TABLE 10:  OTHER BIOCHEMICAL INVESTIGATIONS 
 
Table 10- shows the biochemical investigations on Day 0 and at the end of 8 weeks in 
control and study groups. The differences in lab parameters were not statistically 
significant in both the groups. 
PARAMETER 
GROUP A (CONTROL) GROUP B (STUDY) 
Day 0 
(MEAN) 
AT THE 
END OF 
8WEEKS 
(MEAN) 
P 
VALUE 
DAY 0 
(MEAN) 
AT THE 
END OF 
8 
WEEKS 
(MEAN) 
P 
VALUE 
SGOT 24.87 25 0.894 25.1 24.9 0.86 
SGPT 27.57 27.86 0.814 27.1 27.4 0.96 
BILIRUBIN 0.86 0.85 0.946 0.86 0.83 0.54 
SERUM UREA 28.36 29 0.967 26.93 27.13 0.87 
SERUM 
CREATININE 
0.893 0.884 0.938 0.91 0.87 0.69 
 
 
                          TABLE 11: ADVERSE EVENT PROFILE 
  
                        FIGURE 11: ADVERSE EVENT PROFILE 
 
Fig 11 is a graphical representation of Table 11.                
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ADVERSE EVENT CONTROL GROUP STUDY GROUP 
NAUSEA 3 2 
VOMITING 1 0 
ABDOMINAL PAIN 1 0 
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                             TABLE 12: INCIDENCE OF ADR’S 
 
Table 13 shows the incidence of ADR’s among patients in control and study groups 
which is 10 (33%) and 5 (17%) in the control and study groups respectively. 
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FIGURE 13: MEAN FASTING BLOOD GLUCOSE DURING STUDY AND 
FOLLOW UP PERIOD 
 
FIGURE 14- MEAN PERCENTAGE OF CRENATED RBCs WITH HEINZ 
BODIES DURING STUDY AND FOLLOW UP PERIOD 
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FIGURE 15: MEAN HAEMOGLOBIN DURING STUDY AND FOLLOW UP 
PERIOD
 
FIGURE 16: MEAN RED BLOOD CELL COUNT DURING STUDY AND 
FOLLOW UP PERIOD
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DISCUSSION 
 
Anemia is very common in many chronic inflammatory diseases. The prevalence of 
anemia in Type 2 diabetes is around 25% according to WHO guidelines.85 Anemia is an 
important risk factor in diabetes causing micro- and macrovascular complications of 
diabetes mellitus like retinopathy, nephropathy, neuropathy and delayed wound healing. 
The cause of anemia in not recognized and patients are not treated in Type 2 diabetes. 
Early treatment of anemia is necessary so that the complications of diabetes and insulin 
resistance can be prevented. 
Measuring hemoglobin% alone is not sufficient because the type of anemia cannot be 
assessed. The treatment of anemia varies with the nature of anemia. Therefore, a 
peripheral smear is necessary to find out the exact type of anemia.  
In our study, we used cover slip technique to study the morphology of RBCs under high 
power microscope to find out the exact cause of anemia. 
Oxidative stress plays a major role in the pathogenesis of Type 2 diabetes. Excess 
production of oxidants cause insulin resistance, RBC damage, tissue damage and various 
diabetic complications. 43 
 
 
RBCs are the first cells to be exposed to free radicals and therefore RBCs are susceptible 
to oxidative damage leading to cell membrane defects (crenated edges) and oxidation of 
hemoglobin forming Heinz bodies. 12 
 
The lifespan of RBCs is reduced leading to hemolytic anemia. The oxygen carrying 
capacity of hemoglobin is also reduced. The RBCs lose their shape and flexibility, 
reducing the microvascular circulation and causing various complications like 
retinopathy, nephropathy, neuropathy and non healing of wounds. 
Antioxidants like α-tocopherol (Vitamin E) and ascorbic acid (Vitamin C) scavenge the 
free radicals, protect the cell membrane from oxidative damage and prevent peroxidation 
of lipids. They also reduce insulin resistance by activating tyrosine phosphorylation.69  
Therefore, treatment of anemia with antioxidants like Vitamin E and C in Type 2 diabetes 
protects the RBCs from oxidative damage, decrease insulin resistance and improves 
glycemic control.  
In this study, 102 patients with early Type 2 diabetes (less than 2 years duration) were 
screened, 42 were excluded for various reasons and 60 patients were randomized by 
simple randomization into control and study groups of 30 patients each. The patients in 
the control group were on metformin alone while those in the study group received 400IU 
of Vitamin E and 500mg of Vitamin C once daily along with metformin for 8 weeks 
duration. Both the groups were followed up for 4 weeks post treatment. 
 
 
The level of oxidative stress was assessed on the basis of the percentage of crenated 
RBCs with Heinz bodies along with the hemoglobin level and total RBC count. 
Other parameters assessed were fasting blood glucose, systolic and diastolic blood 
pressure. 
Among the 60 patients who completed the study, the mean age was 48 years and 47 years 
in the control and study groups respectively. This showed that most of the patients were 
middle aged. 
There were a higher proportion of female subjects in both the control (67%) and study 
(63%) groups. 
The mean duration of diabetes was 11 months in control and 9 months in the study group. 
There was no significant difference in any of the parameters assessed at baseline between 
the control and study groups. 
At the end of the 8 week study period, the mean fasting blood glucose was lower in the 
study group (p=0.001) compared to the control group (p=0.030).  This showed that 
adding antioxidants to the standard regimen resulted in decrease in insulin resistance and  
a better control of blood glucose levels.  
Nearly 80% of the RBCs in both the groups showed crenated edges with Heinz bodies at 
the beginning of the study. This indicates the degree of ongoing hemolysis in patients 
with Type 2 diabetes. At the end of 8 weeks, the percentage (%) of crenated RBCs with 
 
 
Heinz bodies was reduced significantly to 6.9% in the study group (p=0.001)  and to only 
76% in control group (p=0.051). This clearly demonstrates that treatment with 
antioxidants improves membrane integrity and reduces RBC fragility and hemolysis by 
preventing free radical induced oxidative damage. 
The mean hemoglobin was below average in both the control (10.37gm/dl) and study 
(10.1gm/dl) groups. After 8weeks of treatment, the study group showed a significant 
increase in hemoglobin (11.45 gm/dl) compared to the control group (10.34gm/dl). 
This proves that anemia in Type 2 diabetes is due to hemolysis induced by oxidative 
damage to RBCs. 
The mean total RBC count was also significantly increased in the study group compared 
to the control group (p=0.003). 
The mean blood pressure was slightly above average in both the groups at baseline. At 
the end of 8 weeks there was a significant reduction in systolic (p=0.042) and diastolic 
(p=0.035) blood pressure in study group compared to control group. This may be 
attributed to the improvement in microcirculation and reduction in total peripheral 
resistance.74 
There was a reduced incidence of adverse effects like nausea, vomiting, abdominal pain 
and hypoglycemia in the study group. 
 
 
All the above mentioned effects were sustained in the study group at the end of the 4 
week follow up period indicating that the beneficial effects of antioxidants persist for 
sometime even after its withdrawal. 
In this study, the improvement in RBC morphology correlated well with the 
improvements in all other parameters like hemoglobin, blood glucose and blood pressure 
due to antioxidant therapy (Vitamin E & C),thus confirming the role of free radicals in 
the pathogenesis of Type 2 diabetes, anemia  and its complications. 
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                                              CONCLUSION 
 
The prevalence of anemia in diabetes was 25% according to WHO guidelines whereas in 
our study anemia was above 80%. 
Treatment of anemia in Type 2 diabetes is not included in the standard regimen. The type 
of anemia also was not given importance. 
In this study, it was proved that the anemia is hemolytic in nature caused by oxidative 
stress. Treatment with antioxidants like Vitamin E and C significantly improved the 
hemoglobin %, RBC morphology and glycemic control in Type 2 diabetes. 
The overall sense of well being was observed in these patients along with significant 
reduction in blood pressure. This proves that stress plays a major role in the pathogenesis 
of Type 2 diabetes and hypertension and antioxidants regulate the sympathetic nervous 
system. 
Treatment of Type 2 diabetes with Antioxidants like Vitamin E and C can arrest the 
disease process, improve glycemic control and prevent the complications of diabetes. 
Using RBC morphology as a marker for oxidative stress is a simple, cost effective and 
novel investigation. 
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RED BLOOD CELL MORPHOLOGY  AS A MARKER OF OXIDATIVE STRESS 
IN EARLY TYPE 2 DIABETES PATIENTS AND EFFICACY OF 
ANTIOXIDANTS AS AN ADD ON THERAPY TO STANDARD TREATMENT  - 
A RANDOMIZED, OPEN LABEL, COMPARATIVE PILOT STUDY 
 
                                      CASE REPORT FORM 
NAME:                                       AGE/SEX       :                PLACE: 
OP No:                                        DIAGNOSIS:   
 
Inclusion criteria:        YES/NO 
 Age: 30-70 years 
 Sex-both genders 
 Patients diagnosed with Type 2 Diabetes Mellitus within 2 yrs 
 Patients on Metformin monotherapy. 
 Patients willing to give written informed consent 
 
EXCLUSION CRITERIA: 
 Patients with Type 1 Diabetes Mellitus 
 Current or ex smokers 
 
 
 Pregnant and lactating women 
 Patients with co-existing liver disease, heart disease, renal disease or malignancy 
 Patients on any lipid lowering drugs 
 Patients with any diagnosed hemotological disorder 
 Patient enrolled in any other study 
 
Subject initials:       Subject number: 
Subject: Included/Excluded                          Reason if excluded:    
Informed Consent Obtained: Yes/No 
CONTROL/ STUDY                       : 
Signature of principal investigator 
Visit 1  
 Randomization done 
 Vital signs recorded 
 RBC morphology studied 
 Fasting blood sugar, haemoglobin and RBC count measured 
 Study medications issued for 4 weeks  
 Instructed  to return empty strips during subsequent visit 
 
 
 Asked to report any adverse event, if any occurs. 
 
Visit 2 (end of 4 weeks) 
 Vital signs recorded 
 Asked for return of empty strips to assess compliance 
 Adverse events recorded, if any 
 RBC morphology studied 
 Fasting blood sugar, haemoglobin and RBC count measured 
 Study medications issued for another 4 weeks  
 
Visit 3 (end of 8 weeks) 
 Vital signs recorded. 
 RBC morphology studied 
 Fasting blood sugar, haemoglobin and RBC count measured  
 Adverse events recorded, if any 
 
Visit 4 (end of 12 weeks) 
 Vital signs recorded 
 Adverse events recorded, if any 
 RBC morphology studied 
 Fasting blood sugar, haemoglobin and RBC count measured  
 
 
 
INFORMATION TO PARTICIPANTS 
 
     
Investigator:  
Name of Participant: 
Title:- RED BLOOD CELL MORPHOLOGY AS A MARKER OF OXIDATIVE STRESS IN EARLY 
TYPE 2 DIABETES PATIENTS AND EFFICACY OF ANTIOXIDANTS AS AN ADD ON THERAPY 
TO STANDARD TREATMENT – A RANDOMIZED, OPEN LABEL, COMPARATIVE PILOT 
STUDY 
This study is conducted at Rajiv Gandhi Govt. General Hospital, Chennai. You are invited 
to take part in this study. The information in this document is meant to help you decide 
whether or not to take part. Please feel free to ask if you have any queries or concerns. 
 
Purpose of this study 
Diabetes is a common metabolic disorder characterized by hyperglycemia due to 
inadequate insulin levels or insulin resistance. A growing body of evidence shows that 
oxidative stress plays a key role in the pathogenesis of vascular changes in Diabetes. In 
this study we want to evaluate the effects of oxidative stress on the morphology of red 
blood cells in Diabetes and the role of Antioxidants in reversing these effects and in 
clinical improvement. 
We have obtained permission from the Institutional Ethics Committee.  
 
 
 
 
 
Study details 
All patients in the study will be divided into 2 groups- A & B. You will be assigned to 
either of the groups. One group will receive the standard treatment & the other group will 
receive standard treatment + Antioxidants 
 
Study Procedures 
During this study, blood will be collected from you twice, once at start of treatment and 
the other at the end of the 8 week treatment period. The total amount of blood collected 
from you will not be more than 2ml. These samples will be used to evaluate your red 
blood cell morphology. You will be asked to come for follow up once after 4 weeks of 
completion of study. During the course of the study if you notice any adverse events, you 
have to report it. You will be required to return unused study medicines when you report 
for your scheduled visits. This will enable correct assessment of the study results. 
 
Possible benefits to you – Antioxidants with your standard medications will reduce the 
level of oxidative stress and your future risk of developing complications due to Diabetes. 
 
 Possible benefits to other people - The results of the research may provide benefits to 
the society in terms of advancement of medical knowledge and/or therapeutic benefit to 
future patients.  
 
 
 
 
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical information 
(personal details, results of physical examinations, investigations, and your medical 
history). By signing this document, you will be allowing the research team investigators, 
other study personnel, sponsors, Institutional Ethics Committee and any person or agency 
required by law like the Drug Controller General of India to view your data, if required. 
The information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
 
Participation and Withdrawal from the study 
Your decision not to participate in this research study will not affect your medical care or 
your relationship with the investigator or the institution. You will be taken care of and 
you will not lose any benefits to which you are entitled. The participation in this research 
is purely voluntary and you have the right to withdraw from this study at any time during 
the course of the study without giving any reasons. However, it is advisable that you talk 
to the research team prior to stopping the treatment/discontinuing of procedures etc. 
The results of this study will be informed to you at the end of the study. 
 
Signature of Investigator                                                  Signature of Participant   
 
Date                                                                                   Date 
 
 
 
 
 
 
 
 
 
INFORMED CONSENT FORM 
 
Red blood cell morphology as a marker of oxidative stress in early Type 2 diabetes 
patients and efficacy of antioxidants as an add on therapy to standard treatment – a 
Randomized, Open label, Comparative Pilot study 
 
Name of the Participant: 
I _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I am over 
18 years of age and, exercising my free power of choice, hereby give my consent to be 
included as a participant in this study. 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I am aware of the fact that I can opt out of the study at any time without having to give 
any reason and this will not affect my future treatment in this hospital. 
6. I hereby give permission to the investigators to release the information obtained from 
me as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC.I understand that they are publicly presented. 
 
 
7. I have understand that my identity will be kept confidential if my data are publicly 
presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, I will be given a copy of this consent 
document. 
 
1. Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name ___________________       Signature_________________ Date_______ 
 
2. Name and Signature of impartial witness (required for illiterate patients): 
Name ______________________ Signature_________________ Date_______ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining consent: 
Name _____________________ Signature_________________ Date_______ 
 
 
 
 
 
 
 
 
 
